Literature DB >> 22941021

Image-guided ablation for hepatocellular carcinoma.

Riccardo Lencioni1, Laura Crocetti.   

Abstract

Image-guided ablation is accepted as the best therapeutic choice for patients with early-stage hepatocellular carcinoma (HCC) when surgical options-including resection and transplantation-are precluded. The term image-guided tumor ablation is defined as the direct application of chemical substances or sources of energy to a focal tumor in an attempt to achieve eradication or substantial tumor destruction. Over the past 25 years, several methods for local tumor destruction have been developed and clinically tested. Radiofrequency ablation (RFA) has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomized controlled trials, and is currently established as the standard ablative modality. Nevertheless, novel thermal and nonthermal techniques for tumor ablation-including microwave ablation and irreversible electroporation-seem to have potential to improve the efficacy of RFA and are currently undergoing clinical investigation.

Entities:  

Mesh:

Year:  2013        PMID: 22941021     DOI: 10.1007/978-3-642-16037-0_12

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  16 in total

Review 1.  Microwave ablation of hepatocellular carcinoma.

Authors:  Guido Poggi; Nevio Tosoratti; Benedetta Montagna; Chiara Picchi
Journal:  World J Hepatol       Date:  2015-11-08

Review 2.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Junichi Shindoh
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

3.  Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients.

Authors:  Jia-yan Ni; Lin-feng Xu; Hong-liang Sun; Jing-xing Zhou; Yao-ting Chen; Jiang-hong Luo
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

4.  Comparison of the effectiveness and safety of ultrasound- and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma.

Authors:  Jing Wu; Ping Chen; Yang-gui Xie; Nian-mei Gong; Lin-lin Sun; Chun-feng Sun
Journal:  Pathol Oncol Res       Date:  2014-12-03       Impact factor: 3.201

Review 5.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

Review 6.  Adverse events of sorafenib in hepatocellular carcinoma treatment.

Authors:  Yongsheng Pang; Aydin Eresen; Zigeng Zhang; Qiaoming Hou; Yining Wang; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

7.  Myofibroblasts: A key promoter of tumorigenesis following radiofrequency tumor ablation.

Authors:  Marwan Moussa; David Mwin; Haixing Liao; M Fatih Atac; Aurelia Markezana; Eithan Galun; S Nahum Goldberg; Muneeb Ahmed
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

Review 8.  Treatment for hepatocellular carcinoma in elderly patients: a literature review.

Authors:  Hiroki Nishikawa; Toru Kimura; Ryuichi Kita; Yukio Osaki
Journal:  J Cancer       Date:  2013-09-14       Impact factor: 4.207

Review 9.  Managing the changing burden of cancer in Asia.

Authors:  Rengaswamy Sankaranarayanan; Kunnambath Ramadas; You-lin Qiao
Journal:  BMC Med       Date:  2014-01-08       Impact factor: 8.775

10.  Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review.

Authors:  Yukio Osaki; Hiroki Nishikawa
Journal:  Hepatol Res       Date:  2014-07-18       Impact factor: 4.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.